Shanghai ZJ Bio-Tech Co. Ltd Class A

As of June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A carries a market capitalization of 2.92B, placing it among publicly traded companies globally. Its enterprise value stands at 419.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A has 192.16M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 23.48, and the price-to-book ratio stands at 0.90.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 419.30M versus a market cap of 2.92B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A maintains a current ratio of 25.38, meaning it holds 25.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.98, indicating elevated leverage, while an interest coverage ratio of -11.55 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A posted a negative return on equity (ROE) of -1.16, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.06, reflecting losses generated across the asset base. The company generates approximately 415,576.19 in revenue per employee across its workforce of 277.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.90 indicates how many times Shanghai ZJ Bio-Tech Co. Ltd Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A recorded an income tax benefit of -8.63M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -47.97M and -39.34M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A's stock has declined approximately 26.49% over the past 52 weeks. The 50-day moving average sits at 17.44, while the 200-day moving average is 18.87.

Over the twelve months ended June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A generated 115.32M in revenue and converted that into -39.34M in net income, yielding earnings per share of -0.22. EBITDA reached -53.68M, while operating income came in at -87.33M.

As of June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A holds 2.79B in cash and equivalents against 292.81M in total debt, resulting in a net debt position of -2.17B. Total book value stands at 3.26B, with working capital of 2.76B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A posted a gross margin of 65.41, reflecting its pricing power and cost economics. The operating margin of -75.73 and net profit margin of -34.12 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A paid dividends of 0.03 per share. The dividend payout ratio of -14.28 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.29, meaning Shanghai ZJ Bio-Tech Co. Ltd Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Shanghai ZJ Bio-Tech Co. Ltd Class A has an Altman Z-Score of 5.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.